Intellia Therapeutics CEO Leonard sells 9,000 shares

The sales were automatic under a Rule 10b5-1 plan adopted May 21, 2026, with reported prices ranging from $11.65 to $12.60.

Available on EDGAR 11/03/2026 - 04:21 PM EST Accepted by SEC EDGAR 11/03/2026 - 04:20 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Intellia Therapeutics, Inc. President and CEO John M. Leonard sold 9,000 shares of common stock on November 2, 2026, at a weighted average price of $11.99 per share. The shares were sold automatically under a Rule 10b5-1 trading plan adopted on May 21, 2026; individual sale prices ranged from $11.65 to $12.60. After the sale, Leonard held 1,138,064 shares directly. A separate holding row lists 58,415 shares held by the John M. Leonard 2015 Irrevocable Trust.

Insider Trade Summary 10b5-1

Net Seller: 9,000 shares

Net Sell 1 txn

Insider LEONARD JOHN M

Role President and CEO

Sold 9,000 shs ($108K)

Share of Position Sold 0.78%

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	9,000	$11.99	$108K
Holding	Common Stock F3	--	--	--

Holdings After Transaction: Common Stock — 1,138,064 shares (Direct); Common Stock — 58,415 shares (Indirect, By Trust)

Holdings Before and After: Common Stock, 1,147,064 to 1,138,064 shares (Direct)

Other Insiders: 1 other insider reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (3)

1. F1. The sales reported on this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2026.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.65 to $12.60, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.
3. F3. Shares held by the John M. Leonard 2015 Irrevocable Trust.

Key Figures

Shares sold: 9,000 shares Weighted average sale price: $11.99 per share Sale price range: $11.65 to $12.60 per share +2 more

5 metrics

Shares sold 9,000 shares November 2, 2026

Weighted average sale price $11.99 per share November 2, 2026

Sale price range $11.65 to $12.60 per share Prices across multiple transactions on November 2, 2026

Direct shares following sale 1,138,064 shares After the November 2, 2026 sale

Shares held by trust 58,415 shares John M. Leonard 2015 Irrevocable Trust

Key Terms

Rule 10b5-1 trading plan, weighted average price, Irrevocable Trust

3 terms

Rule 10b5-1 trading plan regulatory

"automatically pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Irrevocable Trust regulatory

"John M. Leonard 2015 Irrevocable Trust"

An irrevocable trust is a legal arrangement where an owner transfers assets into a separate entity managed by a trustee and gives up the power to modify or reclaim those assets. For investors it matters because putting stock or other holdings into such a trust can change who controls and benefits from the assets, affect taxes and creditor protection, and influence how easy it is to sell or value those holdings—like placing valuables in a locked safe overseen by someone else.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many NTLA shares did John M. Leonard sell, and at what price?

John M. Leonard sold 9,000 shares on November 2, 2026, at a weighted average price of $11.99 per share; individual sale prices ranged from $11.65 to $12.60.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LEONARD JOHN M

(Last) (First) (Middle)

C/O INTELLIA THERAPEUTICS, INC.

400 TECHNOLOGY SQUARE, SUITE 100

(Street)

CAMBRIDGE MASSACHUSETTS 02139

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Intellia Therapeutics, Inc. [ NTLA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/02/2026		S(1)		9,000	D	$11.99(2)	1,138,064	D
Common Stock								58,415(3)	I	By Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported on this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2026.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.65 to $12.60, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.

3. Shares held by the John M. Leonard 2015 Irrevocable Trust.

	/s/ James Basta, attorney-in-fact	11/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)